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Abstract
Objective—We evaluated post-offer pre-placement (POPP) nerve conduction studies (NCS) for 
carpal tunnel syndrome (CTS), testing diagnostic yield and cost-effectiveness.
Methods—1027 newly hired workers underwent baseline NCS, and were followed for an 
average of 3.7 years for diagnosed CTS. Measures of diagnostic yield included sensitivity, 
specificity, and positive predictive value (PPV). Cost-effectiveness of POPP screening was 
evaluated using a range of inputs.
Results—Abnormal NCS was strongly associated with future CTS with univariate hazard ratios 
ranging from 2.95 to 11.25, depending on test parameters used. However, PPV was poor, 6.4–
18.5%. Cost-effectiveness of POPP varied with CTS case costs, screening costs, and NCS 
thresholds.
Conclusions—Although abnormal NCS at hire increases risk of future CTS, the PPV is low, 
and POPP screening is not cost effective to employers in most scenarios tested.
BACKGROUND
Carpal tunnel syndrome (CTS) is a common work related upper extremity musculoskeletal 
disorder and has the longest time away from work and the highest associated direct costs 
among upper extremity work-related injuries and musculoskeletal disorders1–4. Direct 
medical costs are estimated to exceed $1 billion per year1, 3. CTS can also cause significant 
impairment in functional ability for workers in both work and daily activities2, 5, 6. Some 
employers routinely use post-offer pre-placement (POPP) screening including nerve 
conduction studies (NCS) to identify workers at higher risk of developing CTS, so that these 
workers will not be hired into hand-intensive jobs at higher risk of CTS, thus reducing the 
employer’s injury rates and workers’ compensation costs7. It is difficult to estimate the 
Correspondence to: Ann Marie Dale, PhD, Washington University School of Medicine, Division of General Medical Sciences, 
Campus Box 8005, 660 S. Euclid Avenue, Saint Louis, MO 63110; adale@dom.wustl.edu Phone: 314-454-8470; Fax: 314-454-5113. 
Conflicts of Interest
Its contents are solely the responsibility of the authors and do not necessarily represent the official view of NIOSH, NCATS, NIH or 
NeuroMetrix. The authors declare that they have no conflict of interest.
HHS Public Access
Author manuscript
J Occup Environ Med. Author manuscript; available in PMC 2015 August 01.
Published in final edited form as:













number of employers currently utilizing POPP NCS to make hiring decisions; to our 
knowledge there are no published scientific reports describing the prevalence of POPP 
testing by employers. Despite a lack of clear scientific evidence that pre-placement, post-
offer screening with nerve conduction studies is sufficiently predictive of future carpal 
tunnel syndrome, this practice appears to be widespread based on publications in trade 
journals, advertisements by healthcare facilities offering “carpal tunnel testing or 
screening,”8–17 and promotion by device manufacturers.
Studies of active industrial workers have found a high prevalence of asymptomatic nerve 
conduction abnormalities, up to 15–20%18–26. Available studies indicate that asymptomatic 
workers with abnormal nerve conduction studies are at a higher risk of developing CTS than 
asymptomatic workers whose nerve conduction studies are normal18, 27, 28. However, the 
magnitude of the increased risk conferred by nerve conduction abnormalities, the cost 
benefit of doing such screening, and the effectiveness of different work placement strategies 
in preventing carpal tunnel syndrome all remain to be defined.
Another potential limitation of most existing studies is the possibility of a survivor bias 
resulting from selection of subjects who have worked for years in a hand-intensive industry; 
these studies may have evaluated those workers who remained asymptomatic despite work 
demands and abnormalities of nerve conduction29. The predictive value of nerve conduction 
studies (NCS) may thus be different among job applicants than among active workers in 
hand intensive industries. Only one study to date has screened new employees at the time of 
hire and followed their development of CTS longitudinally. This study by Franzblau et al 
(2004)28 studied workers in a single manufacturing plant who received NCS prior to hire, 
but were hired regardless of the results. Results from this study showed that abnormal NCS 
conferred a higher risk for a future workers’ compensation claim for CTS; however, the 
majority of the claims came from workers whose screening NCS were normal at the time of 
hire, and the cost of worker testing exceeded the potential savings that would have resulted 
from not hiring workers with abnormal NCS.
For the purposes of screening, it is unclear whether it is preferable to measure median nerve 
latency via sensory nerve latency, motor nerve latency, or in comparison to ulnar nerve 
latencies. Different testing techniques and different placement of electrodes can alter the 
results obtained30–32. Another important issue in screening studies of asymptomatic persons 
is the need to define what constitutes an “abnormal” test result for working populations. The 
appropriateness of current normative values is questioned by studies showing higher 
prevalence of “abnormal” values among asymptomatic populations of active workers than 
the general population33, 34. It is not clear if the populations from which normative values 
were drawn are truly representative of the worker populations in which the tests are being 
used.
The aim of our study was to determine if nerve conduction studies as part of POPP 
screening for new hires correctly identifies people at risk for CTS across a wide range of 
industries. This study examined the hypothesis that workers with baseline abnormalities of 
median nerve conduction would have a higher incidence of CTS than those with normal 
nerve conduction. In addition, we tested how the prediction yield varied across different case 
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definitions for determining normal and abnormal nerve conduction studies. Finally, we 
estimated the cost-benefit of screening from the perspective of the employer.
METHODS
The Predictors of CTS study (PrediCTS), is a prospective, longitudinal study that recruited 
1107 subjects from eight employers and three trade unions between July 2004 and October 
2006. Subject recruitment took place during company post-offer screenings, new employee 
orientations, or training classes depending upon each employer’s established hiring 
procedures. Eligible subjects were newly hired or had become benefits eligible within the 
prior 30 days, were at least 18 years of age, worked a minimum of 30 hours weekly, and 
were able to speak English. Subjects were excluded if they had a prior diagnosis of CTS or 
peripheral neuropathy, were pregnant at the time of enrollment, or had a contraindication to 
nerve conduction testing. Subjects were recruited from both low and high hand intensive 
jobs and represented a range of industries: construction (carpenters, floor layers, sheet metal 
workers), healthcare (laboratory and hospital technicians), service (food service, 
housekeeping) and clerical work (computer and clerical workers). Detailed information 
about recruitment and data collection methods used for this prospective study has been 
described in several previous manuscripts35–38. The Washington University School of 
Medicine and the University of Michigan Institutional Review Boards approved this study. 
All subjects provided written informed consent and were compensated for their 
participation.
Data collection measures
At baseline, all study subjects received a structured physical examination of the upper 
extremities and bilateral nerve conduction studies. Subjects also completed surveys at 
baseline, 6 months, 18 months, 36 months, and annually thereafter. These surveys collected 
demographic and personal information, work history and physical and psychosocial work 
exposures, and health information including the presence of upper extremity symptoms. On 
each survey, subjects were asked if they had received a new diagnosis for any medical or 
musculoskeletal condition, including carpal tunnel syndrome, in the prior year.
All subjects received nerve conduction studies of the median and ulnar nerves across the 
wrist with the NC-stat automated testing device (Neurometrix Inc, Waltham, MA, USA). 
This device has shown to have good criterion validity compared to traditional 
electrodiagnostic testing methods in studies performed by the manufacturer and in a study 
performed by an independent academic group38–40. Testing was performed by trained 
research technicians according to the manufacturer’s guidelines using techniques described 
in detail in previous publications38, 41, 42. The NC-stat device utilizes preconfigured, nerve-
specific electrodes with embedded temperature sensors. Electrodes were placed on the wrist 
with the distal sensors for the median nerve placed on the third digit and on the fifth digit for 
the ulnar nerve studies. The distance between the wrist sensors and distal finger sensors was 
recorded by the research technician. Distal motor latencies (DML) and distal sensory 
latencies (DSL) were recorded for each nerve and the median-ulnar differences for sensory 
latencies (MUDS) were calculated. Latencies were normalized to a skin temperature of 32 
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degrees Celsius using the manufacturer’s guidelines. Results of NCS were given to each 
participating worker, but this information was not provided to participating employers; no 
hiring or job placement decisions were made based on NCS nor other study findings.
Statistical analysis
For the present study, the main outcome measure was a diagnosis of CTS by a healthcare 
provider as reported by the worker on any follow-up survey, similar to previous studies of 
national health surveillance data43–45. For calculating time to event and time of follow-up, 
workers were censored when a diagnosis of CTS was reported, or at the date of the last 
questionnaire completed for those lost to follow-up or for those without a diagnosis of CTS. 
Presence or absence of hand symptoms at baseline was not included in our case definition; 
in a setting where employment may be contingent upon the results of POPP screening, 
workers may have an incentive to underreport symptoms. The analysis in this study was 
designed to most closely replicate the use of NCS in POPP screening as performed by 
employers.
Chi-square analyses and t-tests were used to compare the mean values of the demographic 
and clinical characteristics, job category, and CTS outcome for workers with normal NCS 
results at baseline and workers with any NCS abnormality at baseline including either 
median DML (>4.5 ms), median DSL (>3.5 ms), or MUDS (>0.5)24. To examine the 
predictive value of POPP NCS on diagnosis of CTS, bivariate survival analysis was 
conducted using time from the baseline survey date to the first survey date when CTS was 
reported. Risk factors were reported as Hazard Ratios (HR). Significant predictors 
(alpha=0.05) were included in the multivariable Cox regression model. The Akaike 
information criterion (AIC) was calculated for each NCS parameter separately, and for the 
composite outcome of any abnormal NCS, to describe which NCS test was the best fit for 
predicting future CTS.
In addition to determining whether baseline NCS was predictive of CTS diagnosis, we also 
examined whether prediction varied based upon the varying definitions of an “abnormal” 
NCS result derived from baseline DML, DSL, and MUDS. We used a range of thresholds 
previously used to identify incident CTS in worker populations and epidemiological 
studies24, 46, 47, in order to show the range of sensitivity and specificity values obtained in 
POPP screening using different thresholds. We computed measures of diagnostic yield 
between future CTS diagnosis and baseline NCS, including sensitivity, specificity, positive 
predictive value (PPV), and negative predictive value (NPV). Using different thresholds and 
NCS tests, we observed how many new workers would need to be screened to correctly 
identify one future CTS case, and how many workers would be incorrectly identified as a 
future CTS case. We repeated these analyses for the right hand only, to determine if testing 
only one hand could be equally predictive as bilateral testing.
Based on these measures, we completed a simple cost-benefit analysis to model a strategy of 
POPP screening from the perspective of the employer, and compared a strategy of not 
screening versus a strategy of performing POPP NCS and not hiring workers whose test 
results were abnormal. In each scenario we calculated the number of workers who would 
need to be screened to attain the same number of workers initially hired. The no screening 
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strategy incurred no screening costs at baseline, but we assigned a cost for each case of CTS 
occurring while employed by the original employer or trade union. The POPP NCS strategy 
was assigned costs for baseline screening, and costs of future CTS cases that were incurred 
only for those subjects screening normal at baseline. Cost-benefit analysis used cost 
estimates of screening and workers compensation costs from a previous cost benefit analysis 
of POPP screening for CTS48. Baseline inputs to our model included a cost per case of CTS 
of $20,000, to represent the total cost of a claim including medical and indemnity costs49, 
and a cost of screening of $150. In addition to the base model, we conducted a sensitivity 
analysis varying the cost of screening and the cost of treatment, to evaluate the degree to 
which our model was affected by assumptions for the cost of screening, the cost of a CTS 
claim, and NCS test characteristics. Different cost estimates for screening were based on 
published reports of actual screening costs from one employer, which included not only the 
cost of NCS screening but other hiring costs such as drug testing, medical evaluations and 
administrative costs28. Different treatment costs were based on published figures for average 
treatment costs for work-related CTS claims in Washington and Ohio states1, 50.
RESULTS
Of the original 1107 newly hired workers screened in the PrediCTS study cohort, 1,027 
(92.8%) completed at least one follow-up survey. Five subjects were excluded because 
baseline NCS results were indeterminate for median DML, DSL, and MUDS. Of the 1,022 
subjects remaining, 35 had partially missing NCS data and were excluded from analyses 
requiring the missing parameters as seen in Tables 2–4. The majority of workers were male 
(64.5%) with a mean age of 30.3 years and a mean BMI of 28.5 (Table 1). A quarter of 
workers had abnormal POPP NCS at baseline. Subjects with abnormal NCS at baseline were 
significantly older, more likely to be male, and to work in the construction trades. The mean 
length of follow-up for the cohort was 3.7 years (range 0.4–6.2). Over the study period 33 
workers reported having received a diagnosis of CTS with a mean time to first report of 
diagnosis of 2.4 years (range 0.4–5.1). Workers with any NCS abnormality at baseline were 
significantly more likely to report a diagnosis of CTS at follow-up. The overall incidence 
rate of CTS diagnosis in the cohort was 8.7 per 1000 person years (PYs). The rate of CTS 
diagnosis was higher among workers with abnormal POPP NCS versus workers with normal 
POPP NCS (22.2 cases per 1000 PYs versus 4.0 cases per 1000 PYs, rate ratio of 5.5 (95% 
CI: 2.6–11.5)).
Baseline NCS abnormality was a statistically significant predictor of future CTS diagnosis 
for all nerve test parameters using our pre-defined cut-points of median DML > 4.5 ms, 
median DSL > 3.5 ms, or MUDS > 0.5 (Table 2). Workers with abnormal MUDS were at 
the highest risk of becoming diagnosed with CTS over the study period, followed by 
abnormal median DSL, any NCS abnormality, or abnormal median DML. Age, gender, and 
BMI were statistically significant predictors of CTS diagnosis. There were no substantial 
changes in the hazard ratios of NCS tests when we repeated these analyses adjusting for age, 
gender, and BMI. Using the AIC to describe the goodness of fit, MUDS had the lowest AIC 
value and thus was a better predictor of CTS than the screening parameters of any NCS 
abnormality, median DML, or median DSL.
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To examine the effect of defining different NCS cut-points for abnormality on the yield of 
screening, including the positive predictive value (PPV) and number needed to test to avoid 
1 future case of CTS, we examined the sensitivity and specificity for the cut-points shown in 
Table 3. As expected for a relatively rare condition, specificity and NPV were high (75.9 – 
93.1%) and (97.5 – 98.8%), respectively; however, sensitivity was low (36.4–65.5%) and 
PPV very low (6.4–18.5%). The most sensitive cut-point, MUDS > 0.5, detected 65.5% of 
those who would later be diagnosed with CTS. While reasonably sensitive, this measure had 
a very poor PPV: only 13.1% of those with an abnormal value based on this cut-point 
reported a diagnosis of CTS over the study period. We repeated these analyses using the 
right hand only; results were similar to the findings of bilateral testing; as expected, 
sensitivity decreased slightly and specificity improved slightly with unilateral testing.
In order to assess the preventive effectiveness of POPP NCS for CTS, we calculated the 
number of job candidates who would need to be screened to avoid 1 future case of CTS 
among the screened workforce using the simple methods previously described by de Kort 
and van Dijk51. Using our pre-defined cut-points, the most sensitive screening parameter, 
MUDS > 0.5, only detected 65.5% of those who would later be diagnosed with CTS, and 
would have required testing 54 subjects to detect 1 future case of CTS in the workforce. At 
the same time, the lower specificity of the MUDS >0.5 parameter would have 
inappropriately denied employment to 7 workers among the 54 who would not have 
developed CTS despite having an “abnormal” NCS test.
In assessing the predictive validity of POPP NCS for predicting future CTS, the analyses 
reported above followed the full cohort of workers including those who changed employers, 
and recorded all cases of CTS during the study period (n=33). We conducted cost-benefit 
analysis from the perspective of the employer, and thus only the 23 CTS cases that occurred 
while a subject screened at baseline was still working for the original employer and had 
complete NCS data were relevant for inclusion in the cost models. In our base case scenario 
using the criterion of “any NCS abnormality” at baseline, 987 newly hired workers were 
screened with POPP NCS; 247 workers would have been rejected for hire, a failure rate of 
25%. In order to attain a work pool of 987 workers who tested normal, a total of 1,317 
workers would need to be screened (987 + 247 replacements from failed screens + 83 
additional replacements due to a continuous failure rate of 25% among replacement workers 
screened). Sixteen of the 23 future CTS cases would have been avoided under a screening 
strategy, as they occurred in the population of workers testing abnormal at baseline using 
this criterion. Seven of 23 CTS cases occurred in the 740 workers screening normal at 
baseline; we used a cumulative incidence rate of CTS in the population screening normal at 
baseline to calculate the expected number of cases in a population of 987 workers screening 
normal at baseline (10 CTS cases when using the testing criterion of any NCS abnormality). 
These case counts and number of workers screened were entered in to our cost model using 
base screening costs of $150 per worker and CTS treatment cost of $20,000 per case, as 
shown in Table 4. The NCS failure rate and number of CTS cases that would have been 
avoided varied with the sensitivity of the NCS parameter used as the screening criterion. 
Cost benefit analysis showed that screening was favored when NCS test sensitivity was high 
(any abnormal NCS, DSL, and MUDS) and cost of screening was low ($150). Using the 
same low screening cost, but a less sensitive NCS measure (median DML >4.5 ms), a no 
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screening strategy was favored. With a higher screening cost ($358), modeled to account for 
the other costs associated with hiring new workers28, a no screening strategy was favored in 
all models, regardless of NCS parameters. These findings were also sensitive to changes in 
treatment cost for CTS. When the treatment cost for a CTS case was varied ($13,253 and 
$5605), using published workers’ compensation data from Ohio for 1999–200450, and 
Washington State 1, a no screening strategy was favored for all NCS screening parameters 
except when using a selection criteria of MUDS >0.5ms with the higher Ohio State costs.
DISCUSSION
The aim of this study was to determine if NCS performed at the time of hire were predictive 
of a future CTS diagnosis among a cohort of workers in a variety of industries. Results 
showed that newly hired workers with abnormal baseline NCS were significantly more 
likely to report a CTS diagnosis during the study period, which is consistent with previous 
studies18, 27, 28. Despite this finding, the predictive validity of such POPP NCS screening is 
at best low or modest. We tested how the prediction yield varied across different thresholds 
for defining normal and abnormal nerve conduction studies, and consistently found low 
positive predictive value across all screening parameters. POPP NCS screening appears to 
be widely used by employers, but our cost-benefit models of screening conducted from the 
perspective of the employer showed that the costs of screening did not outweigh the savings 
for CTS cases that would have been avoided in the majority of scenarios modeled.
The overall rate of CTS in our cohort was 8.7 cases per 1000 person years (PYs), slightly 
higher than the rate of 7.8 per 1000 PYs reported by Franzblau et al28. The slightly higher 
rate of CTS observed in our study population may be partly attributable to our case 
definition of CTS diagnoses reported by workers rather than accepted workers’ 
compensation claims for CTS28. The rates reported in our study and by Franzblau likely 
both underestimate the true occurrence of disease due to untreated or unreported cases33, 52. 
Not all workers who have symptoms are likely to seek treatment, and of those workers who 
seek treatment, not all will file a workers’ compensation claim or have an accepted claim. 
The slightly higher incidence rate in our study may also be attributable to differences in the 
nerve conduction parameters used to identify abnormalities for workers. Our rate is based on 
the screening definition of “any NCS abnormality” (median DSL, DML, or MUDS) at 
baseline, whereas actual test results (latencies, amplitudes, or conduction velocities) were 
not available in the Franzblau study, and thus prediction models were based solely on test 
summaries defined as normal or abnormal. In addition, our study had a longer mean follow-
up time of 3.7 years versus 2.1 years28.
A potential limitation of existing studies is the possibility of a survivor bias resulting from 
selection of subjects who were working for years in a hand-intensive industry18, 27; these 
studies may have evaluated those workers who remained asymptomatic despite heavy work 
demands and abnormalities of nerve conduction29. Jobs in hand-intensive industries often 
have high turnover rates creating a natural selection bias against workers at greater risk of 
developing CTS. Our study and that of Franzblau et al (2004) avoid this potential bias that 
the predictive value of nerve conduction studies (NCS) may be different among job 
applicants than among active workers in hand intensive industries, and thus more closely 
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models the use of NCS as a screening tool during POPP testing. Results from our study 
included workers from a wide variety of industries and employers, while Franzblau’s study 
(2004) included workers from a single employer.
To determine whether the prediction yield of screening for future CTS cases could be 
improved, we evaluated 6 definitions of an “abnormal” NCS result from baseline DML, 
DSL, and MUDS using published thresholds previously used in working populations46, 47. 
Our results showed that the percentage of future CTS cases that were correctly predicted 
was highly dependent upon the definition used to define an abnormal screening result. The 
sensitivity and specificity and positive and negative predictive values of POPP NCS have 
varied, in part because different criteria were used to define normal and abnormal NCS 
measures18, 28. The increased risk of CTS diagnosis in our study varied widely depending 
upon the measure chosen to define an abnormal result from a hazard ratio of 2.95 (95% CI: 
1.45–6.01, p<0.01) for median DML (>4.5ms) to 11.25 (5.22–24.21, p<0.0001) for 
abnormal MUDS (>0.5 ms). As with any diagnostic test, there are explicit trade-offs 
between sensitivity and specificity as seen with use of different criteria for defining 
abnormal nerve conduction studies. As parameter cut-points used to predict the outcome of 
future CTS diagnosis were made more specific, the employers in the study would have 
assumed more risk of potentially hiring workers with greater risk of developing CTS, 
whereas when the cut-points were more sensitive, more healthy workers would have been 
inappropriately excluded from employment. Our results showed very different results 
between different nerve tests and different criteria for defining abnormality. CTS POPP 
screening is often based on testing only the median nerve; in our study we found the highest 
sensitivity and specificity using the median ulnar difference. In our experience, POPP 
testing programs in industry have not formally considered the effects of different cut-points 
or nerve conduction testing techniques in assessing the likely yield and cost-benefit of their 
screening programs, nor have such programs acknowledged the very low positive predictive 
value of POPP testing.
POPP screening with NCS appears to be widely used by employers, but only 2 published 
studies have evaluated its cost-benefit to employers. Evaluation of POPP screening using 
cost data from a manufacturing plant28 found that the cost of screening outweighed potential 
savings from averting workers’ compensation costs for CTS. A cost-benefit modeling 
study48 found that POPP screening for CTS would not be cost beneficial for the majority of 
employers, though could be cost beneficial under circumstances where there was a high cost 
per case and high incidence of CTS. Using these published models, we compared the cost of 
screening the workers in our cohort and not hiring those with abnormal baseline NCS, 
versus a policy of no screening. Our results were consistent with these previous studies, 
showing that POPP NCS screening would not have been cost beneficial to the employer in 
the majority of screening scenarios. When the cost of screening was high, a no screening 
strategy was favored in all cases. As Franzblau (2004) described, there are a number of other 
potential costs associated with screening in addition to a nerve conduction test, which will 
vary depending upon each employer’s hiring practices. These costs may include a medical 
physical examination, drug test (which may or may not be done concurrently with other 
POPP screening), and administrative costs associated with new hire paperwork and 
orientation. In addition, we assigned the same cost of screening regardless of NCS 
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parameter, however, screening parameters which require testing of both the median and 
ulnar nerves (MUDS) would likely cost more than median nerve testing only (DML, DSL). 
Our simplified cost model did not account for screening costs in subsequent years of hiring 
to replace workers lost to turnover, and thus may have not have fully captured costs of 
pursuing a POPP screening strategy.
Cost of treatment for CTS is also highly variable. A 2005 study of work-related CTS claims 
in Washington State1 found a median cost per claim of $5605 over a five-year period, 
though costs for individual cases ranged from $359 to $79,265, depending upon whether 
surgery was performed and when the CTS diagnosis occurred in the course of the claim. Our 
base cost of $20,000 per diagnosed case is very likely to be an overestimate of the costs of 
CTS to employers, as not all diagnosed cases would be claimed under workers’ 
compensation, and not all would be surgical cases. The lower costs seen in Ohio and 
Washington State are more likely to reflect true costs of CTS claims under workers’ 
compensation.
The main limitation of our study was the use of self-reported CTS diagnosis as the outcome. 
As our study was designed to replicate employer practices, CTS diagnosis was a more 
appropriate outcome than an epidemiological case definition, which would have included 
workers who had symptoms and abnormal NCS findings, but who never sought treatment or 
filed a workers’ compensation claim. A similar case definition of self-reported CTS has 
been used in several previous studies of national health surveillance data43–45. Survival 
models were censored at survey date as the actual date of diagnosis was not available. The 
use of an absolute latency for defining an abnormal NCS consistent with CTS has been 
criticized because many factors such as age, temperature, co-morbidities, and BMI can 
influence the absolute latency of the median nerve46. Comparison on the median and ulnar 
latencies controls for these confounding factors and our analysis demonstrated this model 
was the strongest predictor of future CTS. We included all three definitions of abnormal 
NCS because they are still widely used in clinical practice.
Our model showed that screening could be favorable only if the average treatment cost was 
high and the screening cost was low. As discussed in other papers48, 51, for screening to be 
cost beneficial the prevalence of the disorder must be high among new hires, and the 
incidence high following hire. High employee turnover also increases the cost of screening 
and decreases potential employer cost savings as screened workers may leave employment 
before developing the disease of interest48. Our results highlight the sensitivity of the cost-
benefit model to the cost of screening, the cost per CTS case, and the sensitivity of the 
screening test. This relationship highlights the need for employers who utilize POPP 
screening to pick appropriate test cut-points for their workforce rather than a clinical or 
general population. Finally, the cost-benefit of screening should be considered within the 
larger societal context of not hiring otherwise qualified workers. Due to the low PPV of 
POPP NCS screening for future CTS, data from this study showed that each workplace case 
of CTS avoided for the employer would come at the cost of inappropriate denial of 
employment or job placement for 4–15 workers who would not develop CTS during the 
course of their employment. This raises another consideration for employers, the several 
court cases claiming that employers violated the Americans with Disabilities Act or other 
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laws when applicants were excluded from production jobs based on POPP testing for future 
risk of CTS. Although some past cases were settled in favor of the employer (EEOC vs. 
Woodbridge Corporation, 8th Circuit No. 01-L045, August 24th, 2001; EEOC vs. Rockwell 
International Corporation, 7th Circuit Nos. 00–1897 & 00–2034, March 8, 2001), the EEOC 
recently won a discrimination case against an employer who excluded a worker from 
employment based on perceived risk of future CTS.53 While this case was based on 
violation of the Genetic Information Nondiscrimination Act, at least one other lawsuit in 
progress addresses discriminatory aspects of POPP screening by median nerve conduction 
studies.
CONCLUSIONS
Although abnormal NCS at the time of hire is strongly associated with increased risk of 
future CTS, the predictive value of such testing is poor, even when using optimal criteria as 
screening thresholds. The cost of screening and rejecting large numbers of healthy workers 
from employment is high, and in most cases seems to outweigh potential employer cost 
savings from reducing the incidence of CTS in a given workforce. The social costs of 
rejecting otherwise qualified healthy workers from employment should also be considered. 
In all scenarios described above, the vast majority of workers with “abnormal” screening 
results did not develop CTS, and thus would be inappropriately placed or denied 
employment based on a test with demonstrably poor positive predictive value for future 
disease. POPP screening for CTS appears to be widely used, despite ongoing uncertainty 
about ideal screening procedures, appropriate cut-points for screening versus diagnosis of 
clinical median neuropathy, and cost-benefits of the procedure for employers. Employers 
should be cautious in implementing any broad worker screening programs without careful 
consideration of the costs and benefits of such programs. Available evidence shows that 
POPP screening for CTS is poorly predictive of future disease, and published studies to date 
have failed to show that this practice is effective. Occupational health professionals should 
not endorse screening programs that are not based on evidence of benefit to workers’ health.
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Table 1
Demographic and clinical characteristics for the entire cohort at baseline and workers with normal and 










Age 30.3 (10.3) 29.1 (9.6) 34.2 (11.5) 0.0002
Body mass index 28.5 (6.4) 28.0 (6.2) 30.0 (6.8) 0.08
N (%) N (%) N (%)
Gender 0.03
  Female 363 (35.5) 277 (38.4) 74 (30.0)
  Male 659 (64.5) 463 (62.6) 173 (70.0)
Industry <0.0001
  Construction 424 (41.5) 281 (38.0) 133 (53.9) --
  Clerical 366 (35.8) 308 (41.6) 43 (17.4) --
  Service/Technical 232 (22.7) 151 (20.4) 71 (28.7) --
Diagnosis of CTS, number 33 11 20 <0.0001
Person Years of follow-up (PYs) 3777.5 2733.0 900.3 --
Diagnosis of CTS/1000 PYs 8.7 4.0 22.2 --
NCS- Nerve conduction studies, SD- standard deviation, CTS- Carpal tunnel syndrome, ms-milliseconds
*
Temperature and length adjusted, absent values considered abnormal.
†
Abnormal NCS= Any of the following: Median distal motor latency (DML) > 4.5 ms or Median distal sensory latency (DSL) > 3.5 ms or Median-
ulnar sensory latency difference (MUDS)>0.5 ms.
‡
used t-tests for continuous data and chi-square tests for categorical data, comparing those with normal and abnormal NCS at baseline.
§
35 subjects were excluded due to partially missing NCS data.
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